Comparison of outcome and side effects by dose schedule
| Parameter . | 5-day IV dose . | 5-day SQ dose . | 10-day IV dose . |
|---|---|---|---|
| No. of patients | 64 | 14 | 17 |
| No. of patients achieving complete response (%) | 25 (39) | 3 (21) | 4 (24) |
| Median number of courses (range) | 5+ (1-18) | 8 (1-17) | 9 (1-15) |
| Median duration of therapy, mo (range) | 5.4+ (1.0-20.4+) | 9.7 (0.5-22.9+) | 10.8 (1.9-17.7+) |
| Median follow-up time, mo | 6.5 | 15 | 15 |
| No. of patients still on therapy (%) | 39 (61) | 3 (21) | 6 (35) |
| Median days to granulocyte recovery to 1 × 109/L or more | 24 | 14 | 27 |
| Median days to platelet recovery to 50 × 109/L or more | 20 | 31 | 27 |
| Median days to delivery of subsequent courses | 35 | 35 | 40 |
| No. of courses requiring hospitalization (%) | 50 (12) | 14 (14) | 23 (23) |
| Parameter . | 5-day IV dose . | 5-day SQ dose . | 10-day IV dose . |
|---|---|---|---|
| No. of patients | 64 | 14 | 17 |
| No. of patients achieving complete response (%) | 25 (39) | 3 (21) | 4 (24) |
| Median number of courses (range) | 5+ (1-18) | 8 (1-17) | 9 (1-15) |
| Median duration of therapy, mo (range) | 5.4+ (1.0-20.4+) | 9.7 (0.5-22.9+) | 10.8 (1.9-17.7+) |
| Median follow-up time, mo | 6.5 | 15 | 15 |
| No. of patients still on therapy (%) | 39 (61) | 3 (21) | 6 (35) |
| Median days to granulocyte recovery to 1 × 109/L or more | 24 | 14 | 27 |
| Median days to platelet recovery to 50 × 109/L or more | 20 | 31 | 27 |
| Median days to delivery of subsequent courses | 35 | 35 | 40 |
| No. of courses requiring hospitalization (%) | 50 (12) | 14 (14) | 23 (23) |
IV indicates intravenous; SQ, subcutaneous.